Screening for diabetes-related complications (QIIP N=406; control N=403)
| Baseline 12 months prior to LC (%) | During 12 months during LC (%) | Post 12 months after LC (%) | p Value over time | ||
| BP | QIIP | 84.7 | 92.1 | 87.2 | 0.12 |
| Control | 87.8 | 88.1 | 88.6 | ||
| Lipid profile* | QIIP | 72.7 | 84.0 | 76.9 | 0.02 |
| Control | 72.0 | 73.7 | 72.7 | ||
| ACR tested | QIIP | 48.0 | 53.0 | 48.3 | 0.08 |
| Control | 40.7 | 37.7 | 37.5 | ||
| eGFR tested | QIIP | 57.1 | 69.5 | 69.0 | 0.39 |
| Control | 55.6 | 64.0 | 65.0 | ||
| Serum creatinine | QIIP | 73.7 | 83.5 | 80.5 | 0.07 |
| Control | 73.2 | 76.4 | 75.9 | ||
| Foot exam | QIIP | 28.6 | 49.3 | 48.5 | 0.15 |
| Control | 24.8 | 35.0 | 38.0 | ||
| Eye exam | QIIP | 22.4 | 37.9 | 37.2 | 0.03 |
| Control | 18.1 | 20.8 | 27.5 | ||
| Peripheral neuropathy exam† | QIIP | 14.8 | 29.3 | 31.3 | 0.01 |
| Control | 22.8 | 25.1 | 26.6 | ||
| ECG exam | QIIP | 20.4 | 25.9 | 25.4 | 0.22 |
| Control | 14.1 | 14.4 | 19.1 | ||
| Waist circumference documented | QIIP | 7.1 | 21.4 | 25.6 | 0.23 |
| Control | 8.7 | 15.9 | 20.4 | ||
| BMI documented | QIIP | 29.1 | 46.8 | 50.3 | 0.04 |
| Control | 36.7 | 40.2 | 42.9 | ||
*Lipid profile includes: triglycerides, HDL, LDL, total cholesterol:HDL, total cholesterol.
†Vibration or 10 g monofilament testing.
ACR, albumin:creatinine ratio; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; LC,learning collaborative; QIIP, Quality Improvement and Innovation Partnership.